Contrasting INVO Bioscience (NASDAQ:INVO) and Glaukos (NYSE:GKOS)
Contrasting INVO Bioscience (NASDAQ:INVO) and Glaukos (NYSE:GKOS)
INVO Bioscience (NASDAQ:INVO – Get Rating) and Glaukos (NYSE:GKOS – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.
納斯達克(股票代碼：INVO-GET)和Glaukos(紐約證券交易所代碼：GKOS-GET)都是醫藥公司，但哪隻股票更好？我們將根據這兩家公司的盈利能力、估值、風險、股息、機構所有權、分析師推薦和收益等方面的實力進行比較。
Earnings & Valuation
收益與估值
This table compares INVO Bioscience and Glaukos' revenue, earnings per share and valuation.
此表比較了INVO Bioscience和Glaukos的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INVO Bioscience | $4.16 million | 4.51 | -$6.66 million | N/A | N/A |
| Glaukos | $294.01 million | 9.18 | -$49.59 million | ($1.19) | -47.93 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| INVO生物科學 | 416萬美元 | 4.51 | -666萬美元 | 不適用 | 不適用 |
| 格勞科斯 | 2.9401億美元 | 9.18 | -4,959萬元 | ($1.19) | -47.93 |
INVO Bioscience has higher earnings, but lower revenue than Glaukos.
與Glaukos相比，INVO Bioscience的收益更高，但收入更低。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| INVO Bioscience | -222.62% | -165.97% | -92.06% |
| Glaukos | -19.35% | -13.82% | -7.73% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| INVO生物科學 | -222.62% | -165.97% | -92.06% |
| 格勞科斯 | -19.35% | -13.82% | -7.73% |
Insider & Institutional Ownership
內部人與機構所有權
11.8% of INVO Bioscience shares are owned by institutional investors. Comparatively, 93.1% of Glaukos shares are owned by institutional investors. 10.4% of INVO Bioscience shares are owned by company insiders. Comparatively, 8.1% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
INVO Bioscience 11.8%的股份由機構投資者持有。相比之下，Glaukos 93.1%的股份由機構投資者持有。INVO Bioscience 10.4%的股份由公司內部人士持有。相比之下，Glaukos 8.1%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一家公司的長期表現將好於大盤。
Volatility and Risk
波動性和風險
INVO Bioscience has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
INVO Bioscience的貝塔係數為0.19，表明其股價的波動性比標準普爾500指數低81%。相比之下，Glaukos的貝塔係數為1.42，這表明其股價的波動性比標準普爾500指數高出42%。
Analyst Ratings
分析師評級
This is a summary of recent ratings and price targets for INVO Bioscience and Glaukos, as provided by MarketBeat.
這是由MarketBeat提供的INVO Bioscience和Glaukos最近的評級和目標價摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INVO Bioscience | 0 | 1 | 2 | 0 | 2.67 |
| Glaukos | 1 | 4 | 4 | 0 | 2.33 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| INVO生物科學 | 0 | 1 | 2 | 0 | 2.67 |
| 格勞科斯 | 1 | 4 | 4 | 0 | 2.33 |
INVO Bioscience presently has a consensus target price of $2.50, suggesting a potential upside of 62.34%. Glaukos has a consensus target price of $57.38, suggesting a potential upside of 0.59%. Given INVO Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe INVO Bioscience is more favorable than Glaukos.
INVO Bioscience目前的共識目標價為2.50美元，暗示潛在上漲62.34%。Glaukos的共識目標價為57.38美元，暗示潛在上行0.59%。鑑於INVO Bioscience更強勁的共識評級和更高的可能上行空間，股票分析師顯然認為INVO Bioscience比Glaukos更有利。
Summary
摘要
Glaukos beats INVO Bioscience on 8 of the 12 factors compared between the two stocks.
Glaukos在兩隻股票比較的12個因素中有8個超過了INVO Bioscience。
About INVO Bioscience
關於INVO生物科學
(Get Rating)
(獲取評級)
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
INVO Bioscience，Inc.是一家商業階段的生育公司，在全球提供輔助生殖技術解決方案。它的旗艦產品是INVOcell，這是一種醫療設備，可以在女性體內進行受精和早期胚胎髮育。該公司成立於2007年，總部設在佛羅裏達州薩拉索塔。
About Glaukos
關於格勞科斯
(Get Rating)
(獲取評級)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Glaukos公司是一家眼科醫療技術和製藥公司，專注於開發治療青光眼、角膜疾病和視網膜疾病的新療法。該公司提供iStent、iStent注射、iStent注射W型微旁路支架，這些支架可增強白內障手術中植入的房水流出，以治療輕至中度開角型青光眼。該公司的產品線包括iStent InLimited，一種三支架產品，設計用於難治性青光眼患者的獨立手術；以及iDose tr，一種基於其微型設備平臺的定向可注射植入物，旨在提供治療水平的藥物。該公司通過直銷機構以及美國和國際分銷商銷售其產品。Glaukos公司成立於1998年，總部設在加利福尼亞州聖克萊門特。
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得INVO生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對INVO Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。